Skip to main content
In stock | Immunotherapy (Investigational Checkpoint)

Acasunlimab

Oncology Type Solid Tumour
Drug Class / Mechanism Bispecific Antibody, PD-L1 x 4-1BB Conditional Agonist
No Image
Description

Acasunlimab is classified as a Bispecific Antibody, PD-L1 x 4-1BB Conditional Agonist, sourced for use within our Immunotherapy (Investigational Checkpoint) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Immunotherapy (Investigational Checkpoint)
Oncology Type Solid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3